胰高血糖素样肽-1受体激动剂联合二甲双胍对2型糖尿病HOMA-IR、HOMA-β、GSH-Px、ROS、GLUT4及Vaspin的影响分析

The Effect of Glucagon Like Peptide-1 Receptor Agonist Combined with Metformin on the Patients of Type 2 Diabetes and Its Influence of the Levels of HOMA-IR,HOMA-β,GSH-Px,ROS,GLUT4 and Vaspin

目的:探讨胰高血糖素样肽-1受体激动剂联合二甲双胍对2型糖尿病胰岛素抵抗指数(homeostasis model assessment of insulin resistance,HOMA-IR)、胰岛β细胞功能指数(homeostasis model assessment-β,HOMA-β)、谷胱甘肽过氧化物酶(glutathione peroxidase,GSH-Px)、活性氧簇(reactive oxygen species,ROS)、葡萄糖转运蛋白4(glucose transporter 4,GLUT4)及脂肪特异性丝氨酸蛋白酶抑制剂(visceral adipose-specific serine protease inhibitor,Vaspin)的影响。方法:采用随机抽样法选取本院2017年1月-2018年1月收治的2型糖尿病患者84例的临床资料进行回顾性分析,根据治疗方式不同分为对照组与试验组,各42例。对照组予以二甲双胍治疗,试验组予以胰高血糖素样肽-1受体激动剂联合二甲双胍治疗,对比两组治疗前后HOMA-IR、HOMA-β、GSH-Px、ROS、GLUT4及Vaspin水平。结果:治疗后,试验组HOMA-IR(2.26±0.13)与HOMA-β(75.11±5.12)均优于对照组(4.89±0.67)、(65.53±5.19),差异均有统计学意义(P<0.05);治疗后,试验组GSH-Px、GLUT4水平均高于对照组(P<0.05),而试验组ROS、Vaspin水平均低于对照组(P<0.05)。结论:高血糖素样肽-1受体激动剂联合二甲双胍治疗2型糖尿病患者可有效改善HOMA-IR、HOMA-β,提升GSH-Px、GLUT4水平,并降低ROS、Vaspin水平,值得选用。

Objective:To discuss the effect of glucagon like peptide-1 receptor agonist combined with metformin on the patients of type 2 diabetes and its influence of the level of homeostasis model assessment of insulin resistance(HOMA-IR),homeostasis model assessment-β(HOMA-β),glutathione peroxidase(GSH-Px),reactive oxygen species(ROS),glucose transporter 4(GLUT4)and visceral adipose-specific serine protease inhibitor(Vaspin).Method:According to random sampling method,the clinical data of 84 type 2 diabetes mellitus patients in our hospital from January 2017 to January 2018 were selected and retrospectively analyzed.According to different treatment methods,they were divided into control group and experimental group,42 cases in each group.The control group was treated with Metformin,the experimental group was treated with glucagon like peptide-1 receptor agonist combined with Metformin.The levels of the HOMA-IR,HOMA-β,GSH-Px,ROS,GLUT4 and Vaspin in the two groups before and after treatment were compared.Result:After treatment,HOMAIR(2.26±0.13)and HOMA-β(75.11±5.12)in the experimental group were better than(4.89±0.67)and(65.53±5.19)of the control group,the differences were statistically significant(P<0.05).After treatment,the levels of GSH-Px and GLUT4 in the experimental group were higher than those in the control group(P<0.05),while the levels of ROS and Vaspin in the experimental group were lower than those in the control group(P<0.05).Conclusion:The treatment of type 2 diabetes patients with glucagon like peptide-1 receptor agonist combined with Metformin can effectively improve the levels of HOMA-IR and HOMA-β,as well as increase the levels of GSHPx and GLUT4,and reduce the levels of ROS and Vaspin,it is worthy of promotion.